Manufacturer
Takeda Ireland Limited(IRELAND)
Registraction Number
MAL19056102ACRZ
Content:
Each film-coated tablet contains:
Ponatinib (as hydrochloride): 15 mg
Indications:
Chronic Myeloid Leukemia (CML): Used in adult patients with chronic phase, accelerated phase, or blast phase CML who are resistant to dasatinib or nilotinib, intolerant to dasatinib or nilotinib, or have the T315I mutation.
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Used in adult patients with Ph+ ALL who are resistant to dasatinib, intolerant to dasatinib, or have the T315I mutation.
Instructions:
Dosage: The recommended starting dose is 45 mg once daily. Treatment should be continued as long as the patient does not show evidence of disease progression or unacceptable toxicity.
Administration: Take the tablet with or without food. Swallow the tablet whole with water. It is important to follow your doctor's instructions regarding the timing and duration of the medication.
Malaysia
